Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...
A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...
CRISPR Therapeutics has announced promising early-phase results for its CAR T cell therapy, zugo-cel, in several autoimmune ...
CRISPR Therapeutics (CRSP) on Saturday announced new results from a Phase 1 trial for CTX310, an in vivo gene editing therapy for patients with high levels of triglycerides and low-density lipoprotein ...
CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...
In late April 2026, Intellia Therapeutics completed a US$180.00 million follow-on offering of 16,744,187 common shares at US$10.75 each, shortly after reporting that its in vivo CRISPR therapy lonvo-z ...
The U.S. FDA has begun piloting real-time clinical trial tracking in two cancer studies to speed up safety and efficacy monitoring. The move comes as CRISPR Therapeutics attracts investor attention ...
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the ...
Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...
In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results